The Latest Cardiac and Vascular News
NASDAQ: CORV TSX: CORV FDA Accepts Brinavess™ New Drug Application Advisory Committee Date Set for December 10, 2019 PDUFA Date Set for December 24, 2019 Management to Host Conference Call and Webcast Today, November 14, 2019at 8:30 a.m. Eastern (5:30 a.m. Pacific) VANCOUVER, Nov. 14, 2019 /PRNewswire/ – Correvio […]
VANCOUVER, Nov. 4, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that the U.S. Food and Drug Administration (FDA) will hold a Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting […]
VANCOUVER, Sept. 12, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today highlighted that the U.S. Food and Drug Administration (FDA) has accepted for review United Therapeutics Corporation’s (NASDAQ: UTHR) New Drug Application […]
VANCOUVER, July 25, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for […]
VANCOUVER, June 24, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for […]
VANCOUVER, May 8, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today reported financial results for its first quarter ended March 31, 2019 and commented on recent accomplishments and plans. “2019 is off to a […]
VANCOUVER, March 20, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced the presentation of new Brinavess® (vernakalant hydrochloride, IV) data at the American College of Cardiology 2019 Annual Meeting taking place March […]
Company on Track to Resubmit Brinavess NDA in Q2 2019 Mark H.N. Corrigan, MD to Commence CEO Duties on March 14, 2019 Management to Host Conference Call and Webcast Today, March 13, 2019 at 8:00 a.m. Eastern (5:00 a.m. Pacific) NASDAQ: CORV TSX: CORV VANCOUVER, March 13, 2019 /PRNewswire/ […]
VANCOUVER, Feb. 7, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today announced the presentation of clinical data highlighting the low rate of hospitalization in patients treated with Brinavess® (vernakalant hydrochloride, IV), its […]
VANCOUVER, Jan. 17, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today announced the completion of sales of all common shares qualified under its ATM Prospectus Supplement (defined below). The Company’s at-the-market […]
